Skip to main content

Manuel Hernández González

I am immunologist with experience in primary immunodeficiencies and pathologies of the complement system who, in addition to developing the care, teaching and research functions typical of the area of knowledge, I have carried out and carry out tasks related to training, quality and process management. I currently develop my activity as head of the immunology service.

Institutions of which they are part

Main researcher
Translational Immunology
Vall Hebron Institut de Recerca
Head of Department
Cross-departmental services
Since 2017 I have been the head of the immunology service. I have more than thirty years of experience as an immunologist and also experience in the coordination of improvement programs, in providing methodological support in matters of quality of care, in the use of tools for the design of strategic and functional plans and in process management. Master in Direction and Management of Clinical Laboratories. UAB (2000).
I have worked in cellular immunology until 2009 and in immunoproteins from 2010 to the present. I am secretary of the clinical committee for primary immunodeficiencies, vice-president of the subcommittee for the personalization of pharmacological treatments and a member of the clinical committee for complex glomerulopathies. Elected member of the Clinical Board 2022-2024. Member of the In Vitro Diagnosis Commission of the HUVH (2015-). I have participated in quality issues as a member of the Quality Committee of the VH Clinical Laboratories (LCVH) (2011-May 2016), member of the HUVH Quality Support Center (2004-2007) and I have been accredited since 2012 as an auditor Technical Expert in Diagnostic Immunology by ENAC (ISO-15189). I am the president of the LCVH Teaching and Training Commission since June 2017 and a member (2013-16), Tutor of Immunology residents (2011-16), associate professor of the Immunology knowledge area of ​​the Department of Cell Biology, UAB Physiology and Immunology since December 2007, Coordinator of the "Immunodeficiencies" module from 2011 to 2017 and of "Immunopathology" and "Autoimmunity" of the Master's Degree in Advanced Immunology at the UAB-UB from 2021 to the present. I am a doctor in Biology (1996) and a researcher in the "complement pathology" line of the VHIR Traslacional Immunology research group. Coordinator of the immunochemistry working group of the Spanish Society of Immunology (SEI) from 2015 to 2020 and member of the Board of the SEI from 2020 to the present

Research lines

Genetics and immunological factors in COViD-19

Determinants of severity in COVID-19 are still poorly understood but are suspected to be predominantly host factors. Besides age, sex and previous comorbidities, we investigate two other general host factors: 1-Genetic variants causing life-threatening COVID-19: We are mostly focused in genetics of immune system. This research line is under the COVIDHGE consortium. 2-The state of the immune system seems to be an important factor but the immunotypes of risk have not yet been clearly defined. The aim of this line of research is to identify the immune mechanisms that determine the severity of SARS-CoV-2 infection in order to propose and validate biomarkers of prognosis and therapeutic requirements.

IP: Ricardo Pujol Borrell, Manuel Hernández González, Roger Colobran Oriol, Romina Dieli Crimi, Mónica Martínez Gallo

Primary Immunodeficiencies

Our group is focused in the cellular and molecular mechanisms of primary immunodeficiencies (PIDs). Our specific projects include: 1-Expanding the genetic and molecular basis of Primary Immunodeficiencies using high-throughput Technologies. 2-Cellular and molecular basis of hemophagocytic lymphohistiocytosis (HLH). 3-Cellular and molecular basis of common variable immunodeficiency (CVID). PI: Dr. Roger Colobran PI: Dr. Mónica Martínez-Gallo PI: Dr. Clara Franco-Jarava This line is developed in collaboration with the group of "Infection in the immunocompromised pediatric patient" (Head: Dr. Pere Soler-Palacín).

IP: Mónica Martínez Gallo, Manuel Hernández González, Roger Colobran Oriol


Caracterización de Neisseria meningitidis tras la introducción de la vacuna frente al serogrupo B e identificación de factores predisponentes para la enfermedad meningocócica invasiva

IP: Juan Jose Gonzalez Lopez
Collaborators: Manuel Hernández González, Jose Angel Rodrigo Pendás, Aina Aguiló Cucurull, Alba Mir Cros, Albert Moreno Mingorance, Caracterización de Neisseria meningitidis tras la introducción de la vacuna frente al serogrupo B e identificación de factores , Andrea Martín Nalda
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI21/00132
Duration: 01/01/2022 - 31/12/2024


IP: Ricardo Pujol Borrell
Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Marta Miarons Font , Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino , Romina Dieli Crimi, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

Identificación de biomarcadores celulares y moleculares en angioedema idiopático y hereditario para su diferenciación en fenotipos y endotipos

IP: Mar Guilarte Clavero
Collaborators: Manuel Hernández González, Moisés Labrador Horrillo, Anna Sala Cunill, Olga Luengo Sanchez, Ingrid Johana Gil Serrano
Funding agency: Instituto de Salud Carlos III
Funding: 84700
Reference: PI20/01061
Duration: 01/01/2021 - 31/12/2023

Ensayo clínico para comparar la inmunogenicidad de una vacuna anti-hepatitis B adyuvada con la de carga antigénica aunmentada en pacientres inmunodeprimidos.

IP: Magda Campins Martí
Collaborators: Manuel Hernández González, Rosa Lopez Martinez , Lluis Armadans Gil, Laia Pinos Tella, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil
Funding agency: Instituto de Salud Carlos III
Funding: 73205
Reference: PI18/01887
Duration: 01/01/2019 - 30/06/2023

Related news

As age increases in men, the concentration of the hormone in the blood drops and this increases the likelihood of severe progression of the infection in COVID-19 patients

The work used a machine learning system to show that certain immunological patterns are related to a more severe progression of the disease and more mortality.

The publication summarises the main results showing that at least 20% of cases of severe pneumonia after SARS-CoV-2 infection are explained by genetic and immunological anomalies.

Related professionals

Kubra AK

Kubra AK

Read more
Júlia Castellón Teixell

Júlia Castellón Teixell

Read more
Cristina de Dios Conde

Cristina de Dios Conde

Research Support. Licensed Technician
High Technology Unit (UAT)
Preclinical Core Facilities
Core Facilities Area
Read more
Raquel Ibañez Ferrer

Raquel Ibañez Ferrer

Research technician
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.